Format

Send to

Choose Destination
Curr Opin Biotechnol. 2014 Aug;28:51-8. doi: 10.1016/j.copbio.2013.11.005. Epub 2013 Dec 7.

Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.

Author information

1
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
2
School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
3
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA. Electronic address: dap43@cornell.edu.
4
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA. Electronic address: md255@cornell.edu.

Abstract

Vaccine adjuvants are an essential component of vaccine design, helping to generate immunity to pathogen antigens in the absence of infection. Recent advances in nanoscale engineering have created a new class of particulate bionanotechnology that uses biomimicry to better integrate adjuvant and antigen. These pathogen-like particles, or PLPs, can come from a variety of sources, ranging from fully synthetic platforms to biologically derived, self-assembling systems. By employing molecularly engineered targeting and stimulation of key immune cells, recent studies utilizing PLPs as vaccine delivery platforms have shown great promise against high-impact, unsolved vaccine targets ranging from bacterial and viral pathogens to cancer and addiction.

PMID:
24832075
DOI:
10.1016/j.copbio.2013.11.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center